MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Radius Health DSO Ratio 2011-2026 | RDUS
Annual DSO Ratio Radius Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 16.1 | 31.1 | 49 | 61.6 | 73.3 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 73.3 | 16.1 | 46.2 |
Quarterly DSO Ratio Radius Health
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 44.3 | 56.7 | - | 40.3 | 44 | 37.8 | - | 24.3 | 37 | 41.5 | 36.7 | 43.7 | 51.8 | 61.2 | 39.3 | 49 | 67.6 | 66.5 | 96 | 54.6 | 414 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 414 | 24.3 | 68.7 |
DSO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
117 | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
16.5 | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
80.1 | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
71.7 | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
100 | - | - | $ 50.1 M | USA |
 |
Canopy Growth Corporation
CGC
|
62.7 | $ 1.11 | 4.27 % | $ 119 M |  Canada |
 |
Endo International plc
ENDP
|
79.9 | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
63.1 | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
45.7 | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
122 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
203 | $ 2.66 | 2.47 % | $ 1.38 B | Canada |
 |
Evolus
EOLS
|
62.9 | $ 5.19 | 25.54 % | $ 335 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
49.9 | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
134 | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
29.7 | $ 0.58 | 2.89 % | $ 10.1 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
375 | $ 4.18 | -8.73 % | $ 58.8 M | USA |
 |
HEXO Corp.
HEXO
|
71.3 | - | 2.45 % | $ 38.1 M | Canada |
 |
Harrow Health
HROW
|
152 | $ 39.81 | 3.11 % | $ 1.46 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.46 | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
99.8 | $ 3.67 | 5.32 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
89.9 | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
60.9 | $ 8.69 | -2.47 % | $ 445 M | USA |
 |
ProPhase Labs
PRPH
|
111 | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
112 | $ 12.24 | 2.9 % | $ 869 M | USA |
 |
Bausch Health Companies
BHC
|
78.9 | $ 5.63 | -1.66 % | $ 2.05 B | Canada |
 |
Lannett Company
LCI
|
83.1 | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
65.5 | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
72.6 | $ 2.96 | 3.1 % | $ 390 M | USA |
 |
OrganiGram Holdings
OGI
|
93 | $ 1.41 | 2.55 % | $ 402 M | Canada |
 |
Rockwell Medical
RMTI
|
37.5 | $ 0.9 | 0.08 % | $ 21 M | USA |
 |
Perrigo Company plc
PRGO
|
53.9 | $ 11.61 | 1.98 % | $ 1.61 B | USA |
 |
TherapeuticsMD
TXMD
|
2.3 K | $ 2.24 | 0.94 % | $ 23.4 M | USA |
 |
Veru
VERU
|
91.5 | $ 2.67 | 5.95 % | $ 360 M | USA |
 |
Viatris
VTRS
|
78.8 | $ 14.7 | -1.31 % | $ 17.6 B | USA |
 |
Pacira BioSciences
PCRX
|
50.3 | $ 22.6 | 2.26 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
43.1 | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
138 | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
14.1 | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
62.7 | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
11.3 | $ 0.8 | 3.77 % | $ 3.45 M | USA |
 |
SCYNEXIS
SCYX
|
106 | $ 0.77 | 2.75 % | $ 36.8 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
65.5 | $ 2.69 | -2.18 % | $ 3.34 M | USA |
 |
Tilray
TLRY
|
52.8 | $ 7.51 | 2.04 % | $ 4.64 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
14.6 K | - | - | $ 55.5 M | USA |